Herschorn, S., J. Nazir, B. Ramos, and Z. Hakimi. “Supplementary Data: Cost-Effectiveness of Mirabegron Compared to Tolterodine ER 4 Mg for Overactive Bladder in Canada”. Canadian Urological Association Journal, vol. 11, no. 3-4, Apr. 2017, pp. E129-33, doi:10.5489/cuaj.4617.